Labiana Health

Labiana Health Interest Expense

The Interest Expense of Labiana Health (LAB.MC) as of Nov 3, 2026 is -4.89 M EUR. In the previous year, Interest Expense was -3.20 M EUR — a change of 52.62% (lower).

Interest Expense

-4.89 MEUR

YoY

52.62%

Last updated:

Interest Expense of Labiana Health is 2024 -4.89 M EUR. Interest Expense of Labiana Health was 2023 -3.20 M EUR. It decreases by 52.62% lower compared to the previous year.

The Labiana Health Interest Expense history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Expense
Date
Interest Expense
Jan 1, 2018
-569,300.00 EUR
Jan 1, 2019
-1.21 M EUR
Jan 1, 2020
-1.92 M EUR
Jan 1, 2021
-2.66 M EUR
Jan 1, 2022
-1.61 M EUR
Jan 1, 2023
-3.20 M EUR
Jan 1, 2024
-4.89 M EUR
The Labiana Health Interest Expense history
YEARInterest ExpenseYoY
-4.89 MEUR+52.62%
-3.20 MEUR+98.67%
-1.61 MEUR-39.50%
-2.66 MEUR+38.79%
-1.92 MEUR+58.59%
-1.21 MEUR+112.56%
-569,300.00EUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Labiana Health Stock analysis

What does Labiana Health do? Labiana Health SA generates revenue through the development, manufacturing, and marketing of animal and human medicines. The company focuses on drug research and development, including galenic and analytical development, as well as drug manufacturing, which encompasses formulation development and bacterial vaccine manufacturing. Regulatory services for pharmaceutical product registration in global markets also contribute to its income. Its subsidiaries operate in Ecuador, Mexico, Serbia, and Turkey, serving markets for both animal and human pharmaceutical products. The company's primary products include sterile and lyophilized dosage forms, which are manufactured for use in animal and human medicine. These products are sold to customers in the pharmaceutical industry, including distributors and healthcare providers in the regions where Labiana Health SA has a presence. The company’s R&D and manufacturing capabilities support the production of medicines that meet regulatory standards for global markets. Labiana Health SA’s business model relies on its subsidiaries in Ecuador, Mexico, Serbia, and Turkey to facilitate market access and distribution. The company’s revenue streams are derived from the sale of pharmaceutical products, regulatory services, and the development of new drug formulations. Its focus on sterile and lyophilized dosage forms positions it within the specialized pharmaceutical manufacturing sector, targeting both animal and human medicine segments. Labiana Health is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Labiana Health stock

Interest Expense of Labiana Health is -4.89 M EUR in 2024.

Interest Expense of Labiana Health changed from -3.20 M EUR to -4.89 M EUR, representing a 52.62% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Interest Expense Labiana Health since 2006 – with annual values, charts, and detailed analysis.

Interest expense represents the cost of borrowing. Higher interest expenses can indicate a highly leveraged company.

Interest Expense's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Interest Expense's Labiana Health historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Labiana Health

All Key Metrics — Labiana Health